secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001641172-25-026032
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics enters $25M ELOC with White Lion Capital; CFO resigns
------------------------------------------------------------------------

- Entered $25M equity line with White Lion Capital; commitment period through Aug 29, 2028.
- Pricing options include 97% of lowest price in 2-hour window or 20% discount if price below opening.
- CFO Torsten Hombeck resigns effective Oct 10, 2025; will consult through Nov 30 for transition.
- Company must file S-1 resale registration within 30 days; Exchange Cap at 19.99% of outstanding shares.
- Floor price set at $0.20 per ADS; beneficial ownership limit 4.99% (may increase to 9.99% with notice).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000164117225026032/0001641172-25-026032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000164117225026032/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-026032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer